z-logo
Premium
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv
Author(s) -
Doumont Gilles,
Martoriati Alain,
Beekman Chantal,
Bogaerts Sven,
Mee Patrick J,
Bureau Fabrice,
Colombo Emanuela,
Alcalay Myriam,
Bellefroid Eric,
Marchesi Francesco,
Scanziani Eugenio,
Pelicci Pier Giuseppe,
Marine JeanChristophe
Publication year - 2005
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1038/sj.emboj.7600769
Subject(s) - biology , cancer research , g2 m dna damage checkpoint , chek1 , cell cycle checkpoint , microbiology and biotechnology , genetics , cell cycle , cancer
In response to DNA damage, p53 activates a G1 cell cycle checkpoint, in part through induction of the cyclin‐dependent kinase inhibitor p21(Waf1/Cip1). Here we report the identification of a new direct p53 target, Ptprv (or ESP ), encoding a transmembrane tyrosine phosphatase. Ptprv transcription is dramatically and preferentially increased in cultured cells undergoing p53‐dependent cell cycle arrest, but not in cells undergoing p53‐mediated apoptosis. This observation was further confirmed in vivo using a Ptprv null‐reporter mouse line. A p53‐responsive element is present in the Ptprv promoter and p53 is recruited to this site in vivo . Importantly, while p53‐dependent apoptosis is intact in mice lacking Ptprv, Ptprv ‐null fibroblasts and epithelial cells of the small intestine are defective in G1 checkpoint control. Thus, Ptprv is a new direct p53 target and a key mediator of p53‐induced cell cycle arrest. Finally, Ptprv loss enhances the formation of epidermal papillomas after exposure to chemical carcinogens, suggesting that Ptprv acts to suppress tumor formation in vivo .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here